Cagrilintide: FDA records on compounded and unapproved products
Has FDA taken action on compounded cagrilintide?
Yes. As of Nov 15, 2026, FDA has issued 5 warning letters to 5 companies whose text names cagrilintide, the latest dated Mar 31, 2026, and openFDA lists no recall report naming it. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs (FDA page current as of Oct 1, 2026).
As of Nov 15, 2026, FDA’s drug shortage data lists no cagrilintide products.
What FDA has stated, by date
- Oct 1, 2026: FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs. FDA states it has warned telehealth companies for marketing unapproved drugs such as retatrutide, API distributors for selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities for repackaging retatrutide. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
FDA drug shortage status
No cagrilintide entries in FDA’s drug shortage data as of Nov 15, 2026.
Active ingredient (API) imports: FDA import alert and refusal records
This index searches FDA import refusals and import alerts for semaglutide, tirzepatide, liraglutide, retatrutide and the term GLP-1 only; cagrilintide is not searched there. The alert’s Green List and the refusal lines for other GLP-1 drugs are on the GLP-1 import records page.
FDA NDC Directory listings
FDA’s NDC Directory files read Nov 15, 2026 carry 1 listing naming cagrilintide: BULK INGREDIENT (1). Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”
Medicare and Medicaid spending on cagrilintide
CMS’s Medicare Part D Spending by Drug file (2020 to 2024) and Medicaid State Drug Utilization Data (2020 to 2026), read Nov 15, 2026, were searched for cagrilintide by generic and product name; neither lists a product under that name. Other GLP-1 drugs: Medicare and Medicaid spending on GLP-1 drugs.
FDA warning letters naming cagrilintide
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Mar 31, 2026 | Prime Sciences | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | PekCura Labs | Unapproved New Drugs Sold Over the Internet | Cagrilintide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 8, 2025 | Darmerica, LLC | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded | Retatrutide, Cagrilintide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Xcel Research LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Cagrilintide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Summit Research Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Recalls naming cagrilintide
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- CMS Medicare Part D Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.